Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718705 | 0.89 | XDH (0.56) | XDHSMN1; SMN2MAPTRECQL | |
| SCHEMBL4720233 | 0.89 | XDH (0.56) | XDHMAPTRECQLMEN1ALDH1A1 | |
| SCHEMBL4720144 | 0.87 | XDH (0.58) | XDHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4720237 | 0.80 | XDH (0.54) | XDH | |
| SCHEMBL4718708 | 0.79 | XDH (0.53) | XDHSMN1; SMN2MAPTRECQL | |
| SCHEMBL4722573 | 0.77 | XDH (0.53) | XDHSMN1; SMN2MAPTRECQLMEN1 | |
| SCHEMBL4718042 | 0.75 | PDE5A (0.57) | XDHMAPTRECQL | |
| SCHEMBL27613396 | 0.74 | XDH (0.59) | XDHNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4718103 | 0.74 | XDH (0.54) | XDHSMN1; SMN2MAPTRECQLMEN1 | |
| SCHEMBL27594644 | 0.73 | XDH (0.58) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1452528-B1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | NIPPON CHEMIPHAR CO., LTD. | 2007-11-15 | — | — | US | disclosed |
| US-7253154-B2 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20050090472-A1 | Xanthine oxidase inhibitors | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1452528-A1 | XANTHINE OXIDASE INHIBITORS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090472-A1 | Xanthine oxidase inhibitors | XDH, CBR1, NOX1 | XDH 1/4885NPC1 835/4885RAB9A 4676/4885 |
| US-20070265283-A1 | Xanthine Oxidase Inhibitor | XDH, CBR1, NOX1 | XDH 1/4885NPC1 816/4885RAB9A 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.